查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1919422

犬類癌症篩檢市場：按產品類型、技術、癌症類型、檢體類型和最終用戶分類 - 全球預測（2026-2032 年）

Canine Cancer Screening Market by Product Type, Technology, Cancer Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年犬類癌症篩檢市場價值為 3.0597 億美元，預計到 2026 年將成長至 3.2565 億美元，預計到 2032 年將達到 4.1936 億美元，複合年成長率為 4.60%。

關鍵市場統計數據
基準年 2025 3.0597億美元
預計年份：2026年 3.2565億美元
預測年份 2032 4.1936億美元
複合年成長率 (%) 4.60%

權威的導論闡述了臨床需求和診斷技術創新如何融合，從而重新定義犬類癌症篩檢的主動方法

診斷技術的進步和臨床上對伴侶動物腫瘤學日益成長的興趣正在重塑獸醫實踐和研究的重點。過去僅限於健康檢查期間機會性檢測的篩檢模式，正在演變為強調早期發現、微創取樣和綜合診斷的主動式項目。這些變化反映了技術的成熟和飼主對先進治療方案日益成長的需求，共同推動了對能夠更早、更可靠地檢測犬類癌症的工具的投資。

分子診斷技術、生物標記整合和多模態工作流程的進步正在從根本上改變犬類癌症篩檢實踐和決策。

犬類癌症篩檢領域正經歷變革性的轉變，多種因素共同推動診斷方法的開發、檢驗和應用方式的改變。新興的分子平台和定序技術能夠精準地表徵腫瘤生物學特徵，而生物標記檢測技術的改進則提高了早期檢測的信噪比。這些進步，加上與成像策略的整合以及檢體類型的擴展，正在催生出幾年前在技術和經濟上都難以實現的混合工作流程。

評估進口成本波動和關稅導致的供應鏈變化將如何影響犬類癌症診斷的採購模式、檢查室能力和實施時間表。

貿易和關稅政策的變化會對獸醫診斷設備、試劑和服務的整個供應鏈產生顯著影響。當進口關稅和貿易限制導致成像設備、定序平台和特殊試劑的到岸價格波動時，供應商將面臨利潤空間壓縮，並可能考慮推遲資本投資或轉向其他供應商。這些採購趨勢會產生連鎖反應，影響檢查室產能、新檢測方法的推出時間以及診斷服務的地理覆蓋範圍。

深度細分分析揭示了產品類型、技術、最終用戶、癌症類型和檢體模式如何定義不同的開發和商業化路徑。

基於細分市場的洞察揭示了診斷創新與臨床需求和商業性機會的交匯點。依產品類型分類，市場可分為「儀器」、「試劑盒」及「服務」。儀器類別又細分為「影像儀器」、「分子診斷儀器」和「定序平台」。試劑盒包括“ELISA試劑盒”、“NGS試劑盒”和“PCR試劑”，而服務則包括“合約研究”和“檢查室服務”。這種層級結構表明，對平台間互通性和耗材可靠性的投資將決定其普及速度。同時，降低技術壁壘的服務模式可望加速臨床應用。

基礎設施、監管差異以及關鍵區域的臨床應用趨勢如何影響犬類癌症篩檢解決方案的實際部署策略

區域趨勢影響著篩檢項目的可近性、報銷模式和實際部署。在美洲，先進的診斷檢查室和大規模的專業獸醫診所集中分佈，有利於新型檢測方法和影像平台的快速應用。同時，區域法規結構和支付方結構也影響採購週期和服務定價。從都市區向區域診所的過渡需要考慮擴充性、遠距離診斷服務和照護現場能力，以確保公平的醫療服務取得。

診斷和獸醫技術公司推動差異化和臨床應用的關鍵競爭行動和策略重點

主要企業正透過平台擴展、策略聯盟和服務型交付模式相結合的方式，在犬類癌症篩檢獲取價值。現有企業可能會專注於提昇平台相容性，以支援更廣泛的檢測項目並降低檢查室切換成本。同時，專業診斷服務提供者則專注於開發針對特定癌症類型的高靈敏度檢測方法，並力求成為這些適應症的臨床參考標準。

為開發人員、檢查室營運人員和服務供應商提供切實有效的建議，以加速犬類癌症篩檢方案的採用和永續擴展。

產業領導者應優先採取幾項策略行動，將診斷創新轉化為永續的臨床成果。首先，儘早與獸醫腫瘤學家和診斷檢查室接洽，並明確對其臨床實踐至關重要的性能標準，以確保產品開發與臨床可操作的終點指標保持一致。其次，推行模組化平台設計和可互通的測試格式，以減少檢查室在支援不同工作流程和舊有系統時遇到的整合障礙。

本研究採用嚴謹的混合方法研究，將系統性的二次分析與檢驗的原始訪談結合，以確保研究結果的可靠性和實踐導向。

本研究採用的調查方法結合了系統性的二手資料分析和結構化的原始研究，以確保研究結果的穩健性和可重複性。二手資料分析包括查閱同行評審文獻、監管指導文件、專利申請、臨床試驗註冊資料以及製造商的技術規範，以了解技術能力和過往表現。這項桌上研究建立了一個基礎性的分類體系，涵蓋產品類型、技術、最終用戶、癌症類型和檢體收集方式，為後續研究奠定了基礎。

本概要重點闡述了犬類癌症篩檢解決方案成功推廣至臨床應用的關鍵機會和實際考量。

總之，犬類癌症篩檢領域正處於一個轉折點，技術進步、不斷變化的臨床需求和不斷變化的商業性格局交織在一起，為提高早期檢測率創造了具體機會。整合生物標記檢測、基因檢測和標靶成像的多模態診斷路徑正逐漸成為提高敏感性和臨床效用的最有前景的途徑。同時，檢體類型選擇、檢查室能力和區域法規結構等實際因素將決定這些方法應用的速度和範圍。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 犬類癌症篩檢市場（依產品類型分類）

  • 裝置
    • 診斷影像設備
    • 分子裝置
    • 定序平台
  • 試劑和試劑盒
    • ELISA試劑盒
    • NGS試劑盒
    • PCR試劑
  • 服務
    • 委託研究
    • 檢查服務

9. 犬類癌症篩檢市場（依技術分類）

  • 生物標記檢測
    • ELISA
    • 免疫組織化學
  • 基因檢測
    • 基於PCR的
    • 定序定序
  • 影像診斷
    • CT
    • MRI
    • 超音波
    • X光
  • 分子診斷
    • 次世代定序（NGS）
    • PCR
    • 定量PCR

第10章 犬類癌症篩檢市場（依癌症類型分類）

  • 血管肉瘤
  • 淋巴瘤
  • 乳腺腫瘤
  • 皮膚癌

第11章 犬類癌症篩檢市場（依檢體類型分類）

  • 血
  • 細針穿刺
  • 唾液
  • 組織切片檢查
  • 尿

第12章 犬類癌症篩檢市場（依最終用戶分類）

  • 診斷檢查室
    • 臨床檢查室
    • 參考檢驗機構
  • 研究所
    • 學術機構
    • 私人研究機構
  • 動物診所
    • 小動物診所
    • 專科診所
  • 獸醫診所
    • 企業醫院
    • 獨立醫院

第13章 犬類癌症篩檢市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 犬類癌症篩檢市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國犬類癌症篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國犬類癌症篩檢市場

第17章：中國犬類癌症篩檢市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Animal Cancer Care and Research, Inc.
  • Anivive Lifesciences, Inc.
  • Biomerieux SA
  • BluePearl Veterinary Partners, LLC
  • Cancan Diagnostics AB
  • Cutting Edge Laser Technologies, LLC
  • Embark Veterinary, Inc.
  • Heska Corporation
  • IDEXX Laboratories, Inc.
  • LiteCure LLC
  • Mars Petcare, Inc.
  • Oncotect, Inc.
  • Pathway Vet Alliance, Inc.
  • PetDx, Inc.
  • Petnostics Ltd.
  • Siemens Healthineers AG
  • Torigen Specialty Pathology, Inc.
  • VetDC, Inc.
  • VetGen, LLC
  • VolitionRx Limited
  • Wuxi AppTec
Product Code: MRR-F14BA1B3431D

The Canine Cancer Screening Market was valued at USD 305.97 million in 2025 and is projected to grow to USD 325.65 million in 2026, with a CAGR of 4.60%, reaching USD 419.36 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 305.97 million
Estimated Year [2026] USD 325.65 million
Forecast Year [2032] USD 419.36 million
CAGR (%) 4.60%

An authoritative introduction outlining how converging clinical demand and diagnostic innovation are redefining proactive canine cancer screening pathways

Advances in diagnostics and the rising clinical attention to oncology in companion animals are reshaping veterinary practice and research priorities. Screening paradigms that were once limited to opportunistic testing during wellness visits are evolving toward proactive programs that emphasize early detection, minimally invasive sampling, and integrated diagnostics. These shifts reflect both technological maturation and greater owner willingness to pursue advanced care, which together are driving investment in tools that can detect cancer earlier and more reliably in dogs.

Concurrently, collaborations across veterinary clinics, diagnostic laboratories, and research institutes are intensifying, creating pathways for faster validation and clinical uptake of novel assays and imaging modalities. Regulatory evolution and growing emphasis on evidence-based veterinary oncology are further reinforcing the need for robust screening solutions. As a result, stakeholders from device manufacturers to laboratory service providers are recalibrating their strategies to support scalable, clinically actionable screening workflows that balance sensitivity, specificity, cost, and ease of implementation.

How advances in molecular diagnostics, biomarker integration, and multimodal workflows are fundamentally changing canine cancer screening practice and decision-making

The landscape of canine cancer screening is undergoing transformative shifts driven by several converging forces that alter how diagnostics are developed, validated, and deployed. Emerging molecular platforms and sequencing capabilities are enabling more precise characterization of tumor biology, while biomarker assay refinement improves the signal-to-noise ratio for early-stage detection. As these technologies advance, integration with imaging strategies and expanded sample-type compatibility is creating hybrid workflows that were not technically or economically viable a few years ago.

In practical terms, this transformation means that veterinary clinicians and diagnostic laboratories can offer multi-modal screening algorithms that combine blood-based biomarkers, fine needle aspirates, and targeted imaging to stratify risk more effectively. The shift toward personalized diagnostic pathways is also encouraging cross-disciplinary collaborations with human oncology research, accelerating knowledge transfer and translational validation. Ultimately, these developments are changing expectations around screening frequency, turnaround times, and the clinical decision points that follow a positive screen, prompting stakeholders to reimagine service delivery models and reimbursement conversations.

Assessing how changing import costs and tariff-driven supply chain shifts may alter procurement patterns, laboratory capacity, and adoption timelines for canine cancer diagnostics

Policy shifts in trade and tariffs can produce measurable consequences across the supply chain for diagnostic instruments, reagents, and service delivery in the veterinary sector. When import duties or trade restrictions alter the landed cost of imaging equipment, sequencing platforms, and specialized reagents, providers face compressed margins and may delay capital purchases or shift to alternate suppliers. These procurement dynamics then cascade, affecting laboratory capacity, adoption timelines for new assays, and the geographic footprint of diagnostic services.

Beyond direct cost implications, tariffs influence strategic sourcing and inventory management. Diagnostic laboratories and manufacturers respond by seeking localized distribution, negotiating longer-term contracts, or qualifying alternative reagent vendors to mitigate exposure. In an environment where veterinary clinics and hospitals are operating with constrained budgets, changes in import economics can also slow adoption of high-cost platforms and encourage incremental upgrades to existing systems. Consequently, resilience planning, supplier diversification, and adaptive pricing strategies become critical components of organizational risk management.

Deep segmentation analysis revealing how product types, technologies, end users, cancer types, and sample modalities define distinct development and commercialization pathways

Segmentation-driven insights reveal where diagnostic innovation intersects with clinical need and commercial opportunity. Based on Product Type, the market spans Instruments, Reagents & Kits, and Services, with Instruments further divided into Imaging Instruments, Molecular Instruments, and Sequencing Platforms, Reagents & Kits encompassing Eliza Kits, NGS Kits, and PCR Reagents, and Services including Contract Research and Laboratory Services. This layered structure indicates that investments in platform interoperability and consumable reliability will dictate adoption velocity, while service models that lower technical barriers can accelerate clinical implementation.

Based on Technology, screening solutions are organized across Biomarker Assays, Genetic Testing, Imaging, and Molecular Diagnostics, with Biomarker Assays further classified as Elisa and Immunohistochemistry, Genetic Testing splitting into PCR Based and Sequencing Based approaches, Imaging covering CT, MRI, Ultrasound, and X-Ray, and Molecular Diagnostics mapping to NGS, PCR, and QPCR. The diversity of technological routes underscores the need for cross-validation studies and standardized result interpretation to build clinician confidence.

Based on End User, engagement channels include Diagnostic Laboratories, Research Institutes, Veterinary Clinics, and Veterinary Hospitals, with Diagnostic Laboratories subdivided into Clinical Laboratories and Reference Laboratories, Research Institutes split between Academic Institutions and Private Research, Veterinary Clinics differentiated by Small Animal Clinics and Specialty Clinics, and Veterinary Hospitals segmented into Corporate Hospitals and Independent Hospitals. Each end-user cohort has distinct procurement criteria, service expectations, and clinical workflows, making tailored go-to-market approaches essential.

Based on Cancer Type, screening strategies vary by disease biology across Hemangiosarcoma, Lymphoma, Mammary Tumors, and Skin Cancer, requiring assay and imaging modality adjustments to optimize sensitivity and specificity. Finally, based on Sample Type, workflows leverage Blood, Fine Needle Aspirate, Saliva, Tissue Biopsy, and Urine, and the choice of sample materially affects assay design, pre-analytical logistics, and client acceptance. Together, these segmentations map the terrain for prioritized product development, clinical validation pathways, and differentiated commercial models.

How regional infrastructure, regulatory nuance, and clinical adoption trends across major global regions shape practical strategies for rolling out canine cancer screening solutions

Regional dynamics shape access, reimbursement paradigms, and the practical rollout of screening programs. In the Americas, concentration of advanced diagnostic laboratories and a large base of specialty veterinary hospitals supports rapid adoption of new assays and imaging platforms, while regional regulatory frameworks and payer structures influence procurement cycles and service pricing. Transitioning from urban centers to community clinics requires attention to scalability, remote interpretation services, and point-of-care compatibility to ensure equitable access.

Europe, Middle East & Africa present heterogenous markets where regulatory complexity and variable infrastructure create both challenges and localized opportunities. Certain European markets demonstrate strong integration between academic research and clinical practice, enabling rapid evidence generation and specialty referrals, whereas other regions may prioritize low-cost, high-impact screening methods. In the Middle East and Africa, strategic partnerships and capacity-building initiatives can accelerate technology transfer and laboratory network development.

Asia-Pacific features a mix of high-volume urban veterinary services and rapidly growing specialty care, driving demand for cost-effective molecular diagnostics and flexible service models. Manufacturers and service providers targeting this region should plan for diverse regulatory environments, local language support for clinical reporting, and scalable distribution channels that accommodate both metropolitan centers and emerging markets. Across all regions, tailored commercialization strategies that align with local clinical workflows and economic realities will be critical to successful deployment.

Key competitive behaviors and strategic priorities observed among diagnostic and veterinary technology companies driving differentiation and clinical adoption

Leading companies in the diagnostic and veterinary technology space are converging on a combination of platform expansion, strategic partnerships, and service-based delivery to capture value in canine cancer screening. Market incumbents often focus on enhancing platform compatibility to support a broader assay portfolio and to reduce switching costs for laboratories. Simultaneously, a cohort of specialized diagnostics providers concentrates on high-sensitivity assays tailored to specific cancer types, aiming to become the clinical reference standard for those indications.

Partnerships with veterinary hospital networks, research institutes, and contract research organizations are common, enabling rapid clinical validation and broader sample access. Companies are also investing in data analytics and reporting tools to translate complex molecular and imaging results into clear clinical guidance for veterinarians. Finally, firms improving supply chain resilience through regional manufacturing or local distributor networks create competitive advantage by ensuring consistent reagent availability and predictable service levels for diagnostic laboratories and veterinary clinics.

Practical, high-impact recommendations for developers, laboratory operators, and service providers to accelerate adoption and sustainably scale canine cancer screening solutions

Industry leaders should prioritize a few strategic actions to translate diagnostic innovation into sustainable clinical impact. First, align product development with clinically actionable endpoints by collaborating early with veterinary oncologists and diagnostic laboratories to define performance criteria that matter in practice. Second, pursue modular platform designs and interoperable assay formats to lower integration friction for laboratories that must support heterogeneous workflows and legacy systems.

Third, invest in training and support services that reduce implementation risk for veterinary clinics and hospitals, including remote interpretation, standardized reporting templates, and client-education materials that explain screening value and follow-up pathways. Fourth, develop flexible commercial models such as reagent-as-a-service or managed diagnostic services that reduce upfront capital barriers and encourage wider adoption. Lastly, strengthen supply chain resilience through diversified sourcing and regional distribution agreements to mitigate tariff and logistics risks while preserving competitive pricing and service continuity.

A rigorous mixed-methods research approach combining systematic secondary analysis and validated primary interviews to ensure credible, practice-oriented insights

The research methodology deployed for this study combined systematic secondary analysis with structured primary research to ensure robust, reproducible insights. Secondary work included curated review of peer-reviewed literature, regulatory guidance documents, patent filings, clinical trial registries, and manufacturer technical specifications to map technology capabilities and historical performance. This desk research established the foundational taxonomy of product types, technologies, end users, cancer types, and sample modalities that informed subsequent inquiry.

Primary research comprised in-depth interviews with veterinary oncologists, diagnostic laboratory directors, veterinary hospital administrators, and R&D leaders from instrument and reagent suppliers. These interviews explored clinical workflows, validation expectations, procurement drivers, and perceived barriers to adoption. Qualitative findings were triangulated with supplier product documentation and case studies from reference laboratories to validate use cases and implementation scenarios. Where possible, methodological rigor was preserved through cross-validation across independent sources and iterative expert review to minimize bias and ensure practical relevance of conclusions.

Concluding synthesis highlighting the opportunities and practical considerations that will govern successful scale-up of canine cancer screening solutions in clinical practice

In summary, the field of canine cancer screening stands at an inflection point where technological progress, evolving clinical expectations, and shifting commercial dynamics converge to create tangible opportunities for improved early detection. Multimodal diagnostic pathways that integrate biomarker assays, genetic testing, and targeted imaging are emerging as the most promising route to enhance sensitivity and clinical utility. At the same time, practical considerations such as sample type selection, laboratory capabilities, and regional regulatory frameworks will determine the pace and breadth of adoption.

Strategic responses from manufacturers and service providers that emphasize interoperability, evidence generation, and flexible commercial models will be rewarded with broader market access and stronger clinician trust. Operational resilience-particularly in supply chains and regional distribution-remains a key determinant of sustained success. Stakeholders who prioritize clinician collaboration, transparent performance communication, and scalable implementation support will be best positioned to translate diagnostic innovation into measurable improvements in veterinary cancer outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Cancer Screening Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Imaging Instruments
    • 8.1.2. Molecular Instruments
    • 8.1.3. Sequencing Platforms
  • 8.2. Reagents & Kits
    • 8.2.1. Eliza Kits
    • 8.2.2. NGS Kits
    • 8.2.3. PCR Reagents
  • 8.3. Services
    • 8.3.1. Contract Research
    • 8.3.2. Laboratory Services

9. Canine Cancer Screening Market, by Technology

  • 9.1. Biomarker Assays
    • 9.1.1. Elisa
    • 9.1.2. Immunohistochemistry
  • 9.2. Genetic Testing
    • 9.2.1. PCR Based
    • 9.2.2. Sequencing Based
  • 9.3. Imaging
    • 9.3.1. CT
    • 9.3.2. MRI
    • 9.3.3. Ultrasound
    • 9.3.4. X-Ray
  • 9.4. Molecular Diagnostics
    • 9.4.1. NGS
    • 9.4.2. PCR
    • 9.4.3. QPCR

10. Canine Cancer Screening Market, by Cancer Type

  • 10.1. Hemangiosarcoma
  • 10.2. Lymphoma
  • 10.3. Mammary Tumors
  • 10.4. Skin Cancer

11. Canine Cancer Screening Market, by Sample Type

  • 11.1. Blood
  • 11.2. Fine Needle Aspirate
  • 11.3. Saliva
  • 11.4. Tissue Biopsy
  • 11.5. Urine

12. Canine Cancer Screening Market, by End User

  • 12.1. Diagnostic Laboratories
    • 12.1.1. Clinical Laboratories
    • 12.1.2. Reference Laboratories
  • 12.2. Research Institutes
    • 12.2.1. Academic Institutions
    • 12.2.2. Private Research
  • 12.3. Veterinary Clinics
    • 12.3.1. Small Animal Clinics
    • 12.3.2. Specialty Clinics
  • 12.4. Veterinary Hospitals
    • 12.4.1. Corporate Hospitals
    • 12.4.2. Independent Hospitals

13. Canine Cancer Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Canine Cancer Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Canine Cancer Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Canine Cancer Screening Market

17. China Canine Cancer Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Animal Cancer Care and Research, Inc.
  • 18.6. Anivive Lifesciences, Inc.
  • 18.7. Biomerieux SA
  • 18.8. BluePearl Veterinary Partners, LLC
  • 18.9. Cancan Diagnostics AB
  • 18.10. Cutting Edge Laser Technologies, LLC
  • 18.11. Embark Veterinary, Inc.
  • 18.12. Heska Corporation
  • 18.13. IDEXX Laboratories, Inc.
  • 18.14. LiteCure LLC
  • 18.15. Mars Petcare, Inc.
  • 18.16. Oncotect, Inc.
  • 18.17. Pathway Vet Alliance, Inc.
  • 18.18. PetDx, Inc.
  • 18.19. Petnostics Ltd.
  • 18.20. Siemens Healthineers AG
  • 18.21. Torigen Specialty Pathology, Inc.
  • 18.22. VetDC, Inc.
  • 18.23. VetGen, LLC
  • 18.24. VolitionRx Limited
  • 18.25. Wuxi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANINE CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD M